75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - The Company and Liquidity link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Collaboration Agreement with GSK link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - The Company and Liquidity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Summary of Significant Accounting Policies - Summary of Segment Profit or Loss Including Significant Segment Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Commitment and Contingencies - Addtional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Collaboration Agreement with GSK - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Restructuring - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Clinical Trials Clinical trials. Clinical trials Issuance cost of common stock. Issuance Costs Of Common Stock Issuance cost of common stock Restructuring Reserve Restructuring Reserve, Ending Balance Restructuring Reserve, Beginning Balance Restructuring Reserve, Total Restructuring Reserve Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Collaboration revenue member. Collaboration Revenue [Member] Collaboration Revenue [Member] Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental Disclosures: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Remaining contractual maturities of investments were less than one year Long-Term Debt, Excluding Current Maturities Long-Term Debt, Excluding Current Maturities, Total Long-term debt Entity Current Reporting Status Entity Current Reporting Status Operating Expenses [Abstract] Operating expenses: Less: Level 2 Fair Value, Inputs, Level 2 [Member] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Contract with Customer, Refund Liability, Current Refund liability to collaboration partner, current portion Common Stock, Shares Authorized Common stock, shares authorized Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Product and Service [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Entity Shell Company Entity Shell Company Segment Reporting, Policy [Policy Text Block] Segments Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalent Common Stock, Shares, Issued, Total Common stock, shares issued Common Stock, Shares, Issued Number of shares issued Asset Class [Domain] Asset Class Reduction in transaction price Reduction in Transaction Price Reduction in transaction price. Statement [Table] Statement [Table] Restricted Cash, Noncurrent Restricted cash Statement [Line Items] Statement [Line Items] Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Effect of Change in Accounting Estimate, Type [Axis] Entity Filer Category Entity Filer Category Liabilities and Equity Total liabilities and stockholders’ equity Payments to Acquire Marketable Securities, Total Payments to Acquire Marketable Securities Purchase of marketable securities Restructuring Type [Axis] Lease Letter of Credit [Member] Lease letter of credit. Lease letter of credit Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Federal statutory income tax rate Subsequent Event [Line Items] Options to Purchase Common Stock Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents, and Restricted Cash Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Earnings Per Share, Basic Earnings Per Share, Basic, Total Net income (loss) per share, basic Net loss per share, basic Debt, Policy [Policy Text Block] Debt Liabilities, Current Total current liabilities Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Collaboration Payable Collaboration payable. Payable to collaboration partner Equity, Attributable to Parent [Abstract] Stockholders' equity: Entity Small Business Entity Small Business Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Cash Equivalents and Marketable Securities Cash equivalents and marketable securities. Cash Equivalents And Marketable Securities [Member] Clinical supply costs. Clinical supply costs Clinical Supply Costs Stock-based Compensation Share-Based Payment Arrangement [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Contract with Customer, Liability Deferred revenue Contract with Customer, Liability, Total Amendment Flag Amendment Flag Product and Service [Domain] Liabilities and Equity [Abstract] Liabilities and stockholders’ equity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Increase decrease in refund liability to collaboration partner. Increase (Decrease) In Refund Liability to Collaboration Partner Refund liability to collaboration partner Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Common Stock [Member] Common Stock Entity Address, Address Line One Entity Address, Address Line One Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Earnings Per Share [Abstract] Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Document Type Document Type Entity Central Index Key Entity Central Index Key Lab Expenses and Outside Research Services Lab expenses and outside research services. Lab expenses and outside research services Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase in cash, cash equivalents, and restricted cash Subsequent Event Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares Common Stock, Par or Stated Value Per Share Common stock, par value Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Unrealized loss on marketable securities Debt Securities, Available-for-Sale, Amortized Cost Cash equivalents and marketable securities, Amortized Cost Cash Equivalents And Marketable Securities Amortized Cost Cash equivalents and marketable securities amortized cost. Cash equivalents and marketable securities, Amortized Cost Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options (in shares) Income Loss From Operations Income loss from operations. Loss from operations Support Functions Support functions Support functions. Accrued Liabilities, Current, Total Accrued Liabilities, Current Accrued liabilities Current Fiscal Year End Date Current Fiscal Year End Date Document Quarterly Report Document Quarterly Report Entity Address, State or Province Entity Address, State or Province Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Cash equivalents and marketable securities, Unrealized Gains Contract with Customer, Liability, Revenue Recognized Collaboration revenue Marketable Securities, Current Marketable securities Marketable Securities, Current, Total Increase Decrease in accrued liabilities and accrued clinical supply costs. Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs Accrued liabilities and accrued clinical supply costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Recognized Stock-Based Compensation Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Comprehensive Income, Policy [Policy Text Block] Comprehensive Loss Collaborative Arrangement Disclosure [Text Block] Collaboration Agreement with GSK Proceeds from Sale and Maturity of Marketable Securities Proceeds from sale of marketable securities Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Subsequent Event [Member] Subsequent Event Marketable Securities, Policy [Policy Text Block] Marketable Securities Other assets Other Assets, Noncurrent, Total Other Assets, Noncurrent Antidilutive Securities Antidilutive Securities [Axis] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Minimum [Member] Minimum Assets, Current [Abstract] Current assets: Cash And Cash Equivalents And Investments Gross Unrealized Loss Before Tax Cash and cash equivalents and investments gross unrealized loss before tax Cash equivalents and marketable securities, Unrealized Losses Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Financial Assets Measured at Fair Value on a Recurring Basis Liabilities, Current [Abstract] Current liabilities: Restructuring Restructuring and Related Activities Disclosure [Text Block] Contract with Customer, Refund Liability, Total Contract with Customer, Refund Liability Contract with customer, refund liability Commitments and Contingencies Commitments and contingencies (Note 4) Leases Lessee, Leases [Policy Text Block] Increase decrease in payable to collaboration partner. Increase Decrease In Payable to Collaboration Partner Payable to collaboration partner General and Administrative Expense [Member] General and Administrative Effect of Change in Accounting Estimate, Type [Domain] Short-Term Debt Short-Term Debt, Total Short-term debt Amortization of right-of-use assets Amortization right of use asset. Amortization Right Of Use Asset Organization consolidation and presentation of financial statements disclosure table. Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Capital Expenditures Incurred but Not yet Paid Property and equipment purchases included in accounts payable and accrued liabilities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Percentage of development cost. Percentage of Development Cost Percentage Of Development Cost Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average number of shares outstanding basic Shares used in computing net loss per share, basic Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Subsequent Events [Text Block] Subsequent Events APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' equity Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Statement of Stockholders' Equity [Abstract] Type of Restructuring [Domain] Use of Estimates, Policy [Policy Text Block] Use of Estimates Over-Allotment Option [Member] Entity Address, Address Line Two Entity Address, Address Line Two Fair Value Disclosures [Text Block] Fair Value Measurements Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other assets Other assests Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Rule 10B51 Trading Plan Two [Member] Rule 10B51 trading plan one member. Collateral Held [Axis] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Rule 10B5-1 Trading Plan [Member] Rule 10B5-1 trading plan member. Counterparty Name [Axis] Counterparty Name Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Percentage Of Reduction In Workforce Percentage Of Reduction In Workforce Percentage Of Reduction In Workforce Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at beginning of period Total cash, cash equivalents, and restricted cash Interest Paid, Excluding Capitalized Interest, Operating Activity Cash paid for interest Statistical Measurement [Domain] Statistical Measurement Assets, Current Total current assets Share-Based Payment Arrangement, Expense Total stock-based compensation Document Period End Date Document Period End Date Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Statement of Financial Position [Abstract] Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Accrued clinical supply cost. Accrued Clinical Supply Cost Accrued clinical supply costs Liabilities Total liabilities Shares used in computing net loss per share, diluted Weighted-average number of shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Securities Act File Number Entity File Number Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue Available For Sale Securities Debt Maturities Over One Year Through Two Years FairValue Remaining contractual maturities, one year through two years Cover [Abstract] Increase (decrease) in lease liabilities. Increase Decrease In Lease Liabilities Lease liabilities Segment Reporting Information, Profit (Loss) [Abstract] Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets US Treasury Securities [Member] U.S Government Treasury Securities Sale of Stock [Domain] Indemnification agreement liability. Indemnification Agreement Liability Indemnification agreement liability General and Administrative Expense, Total General and Administrative Expense General and administrative Other Officer or Director [Member] Other Officer or Director. Subsequent Event [Table] Restructuring Charges Restructuring Charges, Total Restructuring Charges Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Contract with Customer, Liability, Current Deferred revenue, current portion Employee Severance [Member] Employee Severance Other Segment Expenses Other segment expenses. Other segment expenses Beginning balance (in shares) Common Stock, Shares, Outstanding Ending balance (in shares) Common stock, shares outstanding Operating Lease, Liability, Current Operating lease liabilities, current portion Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Document Transition Report Document Transition Report Operating Expenses Total operating expenses Research and Development Expense, Total Research and Development Expense Research and development Research and development expense Statement of Cash Flows [Abstract] Earnings Per Share [Text Block] Net Loss Per Share Net loss Net loss Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization consolidation and presentation of financial statements disclosure line items. Assets [Abstract] Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Change in Estimate [Member] Change in Estimate [Member] Change in estimate. Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts, Total Restructuring and Related Activities [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities: Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Research and Development Expense [Member] Research and Development Restructuring Cost and Reserve [Line Items] Cash Pledged Agreement Cash Pledged Agreement [Member] Cash pledged agreement. Restricted Stock and Restricted Stock Units Subject to Future Vesting Restricted Stock Awards And Restricted Stock Units [Member] Restricted Stock Awards And Restricted Stock Units [Member] Restricted stock units subject to future vesting ATM Agreement [Member] At The Market Agreement [Member] At the market agreement member. Proceeds from the exercise of options to purchase common stock Proceeds from Stock Options Exercised Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] Company maximum funding. Company Maximum Funding Maximum funding Share-Based Payment Arrangement [Abstract] Rule 10B51 Trading Plan One [Member] Rule 10B51 trading plan one member. Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Cash equivalents and marketable securities, Fair Market Value Sale of Stock [Axis] Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Title of 12(b) Security Title of 12(b) Security OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Unrealized loss on marketable securities Money Market Funds [Member] Money Market Funds Income Tax Disclosure [Text Block] Income Taxes Collaborative Arrangement and Arrangement Other than Collaborative [Table] Other Liabilities, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent, Total Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Income Tax Disclosure [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Additional Paid-in Capital [Member] Additional Paid-In Capital Measurement Frequency [Domain] Measurement Frequency Statement of Income Location, Balance [Axis] Income Statement Location Trading Symbol Trading Symbol Subsequent Event Type [Axis] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities: Fair Value, Recurring [Member] Fair Value, Measurements, Recurring Equity Components [Axis] Accumulated Other Comprehensive Income Equity Component [Domain] Equity Component Asset Class [Axis] Asset Class Collaboration and License Agreement Effective Date Collaboration and License Agreement Effective Date Effective date of agreement Cash And Cash Equivalents And Investments Gross Unrealized Gain Before Tax Cash and cash equivalents and investments gross unrealized gain before tax. Cash equivalents and marketable securities, Unrealized Gains Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Statement of Comprehensive Income [Abstract] Maximum [Member] Maximum Statistical Measurement [Axis] Statistical Measurement Contract with Customer, Liability, Noncurrent Deferred revenue, long-term portion Transactions Price. Transactions Price Transaction price Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Common stock, $0.0001 par value; 200,000,000 shares authorized; 111,025,187 and 110,362,581 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively Number Of Reduction In Workforce Number Of Reduction In Workforce Number Of Reduction In Workforce Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Effective tax rate Milestone payment received Proceeds from Collaborators Additional milestone payments to support the enrollment Agency bond . Agency Bonds [Member] Agency Bonds Employee Stock [Member] Shares Committed Under 2019 ESPP Entity Registrant Name Entity Registrant Name AbbVie biotechnology, limited. Abb Vie Biotechnology Limited [Member] AbbVie Biotechnology Limited Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cash equivalents and marketable securities, Unrealized Losses Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other income, net Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional Paid in Capital Additional paid-in capital Subsequent Events [Abstract] Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income tax expense Measurement Frequency [Axis] Fair Value, Measurements, Recurring Proceeds from Issuance of Common Stock Net proceeds from the sale of securities Proceeds from issuance of common stock, net of issuance costs Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Stock-based Compensation Compensation Related Costs, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Additional milestone payments related to initiation of certain clinical studies and regulatory approval Collaborative Arrangement Additional Milestone Payments Receivable Collaborative arrangement, additional milestone payments receivable. Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Assets Total assets Restructuring Cost [Table] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs (in shares) Public offerings Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net income (loss) per share, diluted Net loss per share, diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Summary of Segment Profit or Loss Including Significant Segment Expenses Grace Wong Sarad [Member] Grace Wong Sarad. City Area Code City Area Code GSK [Member] GSK [Member] GlaxoSmithKline plc Upfront payments Collaborative arrangement, upfront payments. Collaborative Arrangement Upfront Payments Counterparty Name [Domain] Counterparty Name Alector. Alector [Member] Alector Vesting of restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Gross Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net Property and equipment, net Corporate Bond Securities [Member] Corporate Bonds Operating Income (Loss) Loss from operations Retained Earnings [Member] Accumulated Deficit Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Operating Lease, Liability, Noncurrent Operating lease liabilities, long-term portion Fair Value, Inputs, Level 1 [Member] Level 1 Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Collateral Held [Domain] US Government Corporations and Agencies Securities [Member] U.S. government agency securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share Entity Interactive Data Current Entity Interactive Data Current Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase decrease to collaboration revenue Statement of Income Location, Balance [Domain] Income Statement Location Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities: Accretion (Amortization) of Discounts and Premiums, Investments Amortization of premiums and accretion of discounts on marketable securities Increase (Decrease) in Other Noncurrent Liabilities Other long-term liabilities Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value, Total Cash equivalents and marketable securities, Amortized Cost Entity Tax Identification Number Entity Tax Identification Number Certificate of deposit . Certificates of Deposit [Member] Certificates of Deposit Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] The Company and Liquidity Credit losses on marketable securities Marketable Security, Unrealized Gain (Loss) Local Phone Number Local Phone Number Accounting Policies [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Commercial Paper [Member] Commercial Paper Labor and Related Expense Compensation and benefits Entity Emerging Growth Company Entity Emerging Growth Company